Alkyl Amines Chemicals Ltd (ALKYLAMINE) faced a challenging session today, with the stock sliding to a closing price of 1,491.90. This level represents a critical technical junction, as the stock has now retraced significantly from its post-pandemic highs to test investor patience at multi-year support zones.
The Price: Key Benchmarks
The stock’s volatility today saw it touch an intraday low of 1,482.00 before settling slightly higher.
| Metric | Value (INR) | Context |
| Today’s Closing Price (25/02/26) | 1,491.90 | Down ~1.1% from the previous session. |
| 52-Week High | 2,438.80 | Reached during the recovery attempt in mid-2025. |
| 52-Week Low | 1,482.00 | Hit during today’s trading session. |
| Life-Time High | 4,749.00 | Scaled in mid-2021 (the specialty chemical “super-cycle”). |
| Life-Time Low | 7.35 | Historical base (adjusted for splits and bonuses). |
A Decade of Growth: 10-Year Financial Summary
The table below illustrates the company’s journey from a small-cap player to a market leader, and the subsequent margin pressure seen in the last 24 months.
| Fiscal Year | Sales (Cr) | Operating Profit (Cr) | OPM % | Net Profit (Cr) | EPS (INR) |
| 2017 | 501 | 95 | 19% | 50 | 9.87 |
| 2018 | 616 | 118 | 19% | 64 | 12.61 |
| 2019 | 846 | 164 | 19% | 84 | 16.42 |
| 2020 | 993 | 257 | 26% | 215 | 42.21 |
| 2021 | 1,242 | 430 | 35% | 295 | 57.91 |
| 2022 | 1,542 | 326 | 21% | 225 | 44.04 |
| 2023 | 1,683 | 348 | 21% | 229 | 44.75 |
| 2024 | 1,441 | 252 | 17% | 149 | 29.12 |
| 2025 (E) | 1,572 | 291 | 19% | 186 | 36.40 |
| 2026 (TTM) | 1,535 | 282 | 18% | 181 | 35.33 |
10-Year Stock Price Visualization (2016–2026)
The chart below tracks the stock’s transition from a steady climber to a parabolic peak and its current consolidation phase.
Price (INR)
| [Peak: 4,749]
| / \
4k| / \
| / \
3k| / \
| / \_________
2k| / \
| _________/ \____ [Current: 1,491.90]
1k|_____/
|___________________________________________________________
2016 2018 2020 2021 2023 2025 2026
Valuation & The “Book Value” Reality
-
Book Value (BV): ~282.17.
-
Current P/B Ratio: 5.28x.
-
Relevance: While a P/B of 5x is significantly lower than the 12x-14x seen in 2021, it still suggests that the market expects Alkyl Amines to deliver Return on Equity (ROE) far above the cost of capital. The narrowing gap between the Current Market Price (1,491.90) and its DCF Intrinsic Value (~1,515) indicates that much of the “hype” has finally been priced out.
Strengths & Weaknesses
Strengths:
-
Virtually Debt-Free: A fortress balance sheet with negligible interest costs.
-
High Promoter Skin-in-the-Game: Promoters hold ~72%, signaling long-term confidence.
-
Capital Efficiency: Despite the slump, ROCE remains healthy at ~18-19%.
Weaknesses:
-
Raw Material Dependency: Heavily reliant on Methanol and Ethyl Alcohol; any price spike in these commodities directly hurts the bottom line.
-
Concentration Risk: Heavy reliance on the Pharmaceutical sector (over 50% of revenue) makes them vulnerable to generic drug cycles.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should verify all information from official exchange filings and consult a registered financial advisor before making investment decisions.